Liver Cancer
Conditions
Keywords
Cinobufacini
Brief summary
The clinical trail of Cinobufacini combined with TACE on primary liver cancer.The trail is randomized controled.Patients are diagnosed primary liver cancer based on pathology or cell biology.They are randomized into 2 groups:both groups receive TACE.The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months..The control group only receives TACE.Mainly to study Cinobufacini leads to the influence of the immunologic function after TACE.Immunological examination and Blood biochemistry evaluation include the number ratio、activity and function of immune cell,the immune cell marker(CD3、CD4、CD8,etc),tumor marker(CEA、AFP),etc.Clinical evaluation includes image data(CT/MRI),drug toxicities,quality of life(QOL),etc.
Detailed description
The clinical trail of Cinobufacini combined with TACE on primary liver cancer.The trail is randomized controled.Patients are diagnosed primary liver cancer based on pathology or cell biology.They are randomized into 2 groups:both groups receive TACE.The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months..The control group only receives TACE.Mainly to study Cinobufacini leads to the influence of the immunologic function after TACE.Immunological examination and Blood biochemistry evaluation include the number ratio、activity and function of immune cell,the immune cell marker(CD3、CD4、CD8,etc),tumor marker(CEA、AFP),etc.Clinical evaluation includes image data(CT/MRI),drug toxicities,quality of life(QOL),etc.
Interventions
The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
DRUGcinobufacini tablet
The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
Sponsors
The First Affiliated Hospital of Dalian Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age:18-70 years. * male and female. * signed the informed consent form. * Diagnosis:Primary liver cancer diagnosed by imaging、cell and pathology report. * Eastern Cooperative Oncology Group (ECOG) :0-2;life expectancy more than 3 months. * Indication for TACE,no contraindication. * First time chemotherapy or at least 6 months after last chemotherapy and radiotherapy. * At least 8 weeks after last biotherapy. * Surgery：had not received transplantation surgery,at least 2 weeks after last major surgery.
Exclusion criteria
* Chemotherapy is contraindicated. * Have the primary disease can cause the neuropathy. * A history of other malignant tumor in recent 5 years. * Less than 6 months after last chemotherapy or radiotherapy. * Less than 8 months after last. * Cinobufacini allergy. * Had received transplantation surgery ,less than 2 weeks after last major surgery. * Other researchers think is not suitable for this clinical trail.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor size | the 8th week after TACE operation |
Secondary
| Measure | Time frame |
|---|---|
| the number of CD4+T cell,CD8+T cell in blood | the 8th week after TACE operation |
| Interleukin(IL)-2,Interleukin(IL)-4,Interleukin(IL)-6,tumor necrosis factor(TNF)-α，interferon(INF)-γ in blood | the 8th week after TACE operation |
Countries
China
Contacts
Primary ContactXiaonan Cui, MD,PhD
Backup ContactJian Zhang
Outcome results
None listed